Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/17/2025

Management of Electrolyte Abnormalities in Impaired Renal Function

Initial Assessment and Urgent Management

  • The American College of Cardiology recommends immediately discontinuing both potassium and calcium supplements in patients with hyperkalemia, hypercalcemia, and worsening renal function 1, 2
  • For severe hyperkalemia (K+ >6.0 mEq/L) or with ECG changes, administer IV calcium gluconate (1,000 mg) to stabilize cardiac membranes, give insulin (10 units IV) with glucose (50 ml of 50% solution) to shift potassium intracellularly, and consider sodium bicarbonate IV if metabolic acidosis is present 3

Medication Adjustments

  • The American College of Cardiology recommends discontinuing all medications that can worsen hyperkalemia, including potassium supplements, ACE inhibitors or ARBs, potassium-sparing diuretics, and NSAIDs 1, 4, 5

Monitoring and Follow-up

  • Check serum potassium, calcium, and renal function within 24 hours and then daily until stable, and monitor ECG continuously in severe cases or at least daily in moderate cases 1, 3
  • For patients with K+ >5.5 mEq/L, recheck potassium levels within 2-3 days 1, 2
  • Continue to monitor renal function closely, as worsening renal function can further exacerbate both electrolyte abnormalities 6

Long-term Management

  • Once acute electrolyte abnormalities are corrected, counsel patients on avoiding high-potassium foods and salt substitutes, and consider dietary consultation for both potassium and calcium restriction 1, 7
  • If RAAS inhibitors (ACE inhibitors/ARBs) are necessary for the patient's condition, consider adding an SGLT2 inhibitor which may help reduce hyperkalemia risk 6
  • For recurrent hyperkalemia, consider newer potassium binders (patiromer or sodium zirconium cyclosilicate) 6, 3

Common Pitfalls to Avoid

  • Avoid the triple combination of ACE inhibitors, ARBs, and aldosterone antagonists due to high risk of hyperkalemia 1, 2
  • Remember that renal impairment increases risk of both hyperkalemia and hypercalcemia, requiring more frequent monitoring 1, 6

REFERENCES